Brief: Kinnate Biopharma Inc. To Report First Clinical Data For Its Investigational Pan-Raf Inhibitor, Exarafenib (Kin-2787), In An Oral Presentation At The Aacr 2023 Annual Meeting
14/03/2023 22:39
March 14 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. TO REPORT FIRST CLINICAL DATA FOR
ITS
INVESTIGATIONAL PAN-RAF INHIBITOR, EXARAFENIB (KIN-2787), IN AN
ORAL PRESENTATION AT THE AACR 2023 ANNUAL MEETING
* KINNATE BIOPHARMA INC: COMPANY HAS INITIATED ENROLLMENT OF
PATIENTS INTO MONOTHERAPY EXPANSION COHORTS OF TRIAL
Source text for Eikon: ID:nGNX1MQZYp
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview